News
New research on genetic risk and breast cancer
New Norwegian research in polygenic risk score
A roadmap for the health industry
What is the government's ambition for the health industry?
Personalised medicine to relieve the health service
Smaller patient groups and targeted treatments are the future of cancer care in Norway. It is no longer a question of if but when personalised medicine will be a reality for all cancer patients in Norway. This was a key message in a recent meeting arranged by the public-private consortium CONNECT during Arendalsuka, where the […]
Arendalsuka: – We need to attract the big companies
How will Norway implement the Mission on Cancer?
Arendalsuka 2023
Møt oss i Arendal! Vi snakker om kreftinnovasjon med politikerne.
AI for more precise radiation therapy
Learn how artificial intelligence is changing radiation therapy.
Gilead joins Oslo Cancer Cluster
Gilead is a biopharmaceutical company advancing innovative medicines
Polygenic risk scores: a European cancer priority
Polygenic risk scores can improve prevention and early detection of cancer.
New targeted therapy against osteosarcoma
Research group in Oslo Cancer Cluster Incubator develops new cancer treatment
Oncology innovators presented in Boston
Three Nordic start-ups pitched at the International Cancer Cluster Showcase 2023. This year’s International Cancer Cluster Showcase (ICCS) featured 20 emerging oncology companies that presented their recent innovations, partnering and investment opportunities on 5 June 2023 in Boston, as a satellite event to BIO International Convention. The companies were selected by innovation hubs in the […]
Cancer start-ups met investors
Investors wanted to learn about Norwegian cancer companies.
Forenkler testing av helseteknologi sammen
NorTrials Medisinsk utstyr har inngått en samarbeidsavtale med HealthCatalyst AS.
